The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma.
Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF. BRAF status is key for assessing treatment options.
Results from tests completed under the Know Now Testing Program are available approximately 48 hours after a Quest Diagnostics laboratory receives a sample, which could lead to timely and optimal treatment decisions, Novartis says. To access the Know Now program and its no-cost testing, healthcare professionals should visit KnowNowBRAF.com and download the BRAF Test Request Form.
"At Novartis, we know that understanding potential mutations is critical for melanoma patients and their doctors to make informed treatment decisions," said Ameet Mallik, Executive Vice President and Head, US, Novartis Oncology. "We recognize the barriers that often keep patients from being tested. That's why we're empowering the melanoma community with this Know Now Testing Program."
People diagnosed with stage III or stage IV melanoma can ask their doctor about BRAF testing and the Know Now Testing Program to access its no-cost testing benefit. Healthcare professionals can also visit KnowNowBRAF.com.